A large-scale clinical trial conducted by the National Cancer Institute found that one dose of an HPV vaccine is just as protective against infection as the traditional 2-dose regimen. The randomized study, which enrolled more than 20,000 girls aged 12 to 16 years, compared the effectiveness of 1 and 2 does of the bivalent Cervarix (GlaxoSmithKline) vaccine and the 9-valent Gardasil 9 (Merck) vaccine. Participants were assigned to receive either dosing regimen, and both groups …
Read More